Multiple Sclerosis

Featured Article
The first phase 3 trial comparing ponesimod to teriflunomide found ponesimod to be more effective at reducing the annualized relapse rate in multiple sclerosis (MS) patients.
The US Food and Drug Administration has recently approved ponesimod, an oral treatment, for adults with relapsing multiple sclerosis.
Which of the following is a risk factor for developing multiple sclerosis?
In this podcast, Dr Huang discusses various research models that he, his colleagues, and others are currently using to examine potential remyelination strategies for multiple sclerosis. Dr Huang recently gave a talk about this topic at the American Neurological Association's 145th Annual Meeting.
According to recent estimates, how many people in the United States have multiple sclerosis?
In a bidirectional Mendelian randomization study, researchers used recent genome-wide association study data to further examine the relationship between multiple sclerosis and depression.
Individuals can develop multiple sclerosis (MS) at any age, but during which age range does MS most commonly occur? Test your knowledge in our pop quiz.
Multiple sclerosis has been described for centuries, though physicians at the time did not have a name for the condition. In what year was multiple sclerosis officially recognized in the United States?
In this podcast, Patricia K. Coyle, MD, discusses anticipated developments in the field of multiple sclerosis this year, including clinical trial data, COVID-19 vaccination, wearable devices, and more. A full transcript is provided.
In a recent analysis of 26 trials that had examined 14 disease-modifying therapies (DMT) among patients with relapsing-remitting multiple sclerosis, researchers aimed to examine whether age impacted DMT efficacy.
Should health care practitioners counsel men with multiple sclerosis on their reproductive plans before starting pharmacological treatment? Test your knowledge in our latest pop quiz!